Amir Fathi, MD, leukemia specialist at Massachusetts General Hospital, discusses the importance of advocacy by both patients ...

Schrödinger is discontinuing the development of its blood cancer CDC7 inhibitor after two patient deaths. In a Phase I trial ...

Schrödinger Inc (NASDAQ:SDGR) shares dropped 13.7% following the company’s announcement that it is discontinuing development ...

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute ...

Schrödinger is abandoning its CDC7 inhibitor after the therapy was linked to the deaths of two patients in a phase 1 leukemia trial. The biotech had been evaluating the asset, dubbed SGR-2921, in an ...

SGR-2921 was being evaluated in an early-stage study in patients with relapsed/refractory acute myeloid leukemia or high-risk ...

Schrodinger discontinued its study of a potential treatment for acute myeloid leukemia or high-risk myelodysplastic syndromes, citing patient deaths linked to the treatment.

GAAP EPS was $(0.49) for Q2 2025, missing analyst estimates by 22.3%. Moleculin Biotech (NASDAQ:MBRX), a clinical-stage pharmaceutical developer focused on oncology, released its second quarter 2025 ...

Researchers sought to determine whether elderly, fit patients with AML would respond to therapy with venetoclax plus modified intensive chemotherapy.

There's light at the end of the tunnel for Kendall Schara in her fight against Acute Myeloid Leukemia, after her sister Elle ...

RedChip Companies will air interviews with Aptevo Therapeutics, Inc. (NASDAQ:APVO) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip Small Stocks, Big Money™ show, a sponsored program ...

Professor Xun Lan from the School of Basic Medical Sciences at Tsinghua University and Director Hongxing Liu from Hebei Yanda ...